Instil Bio, Inc. (TIL)
NASDAQ:TIL
Top Page
Instil Bio
(NASDAQ:TIL)
Select Model
Select Model
Rating:43Neutral
Price Target:
$7.50
▼(-6.60% Downside)
Action:ReiteratedDate:03/28/26
The score is primarily weighed down by weak financial performance (minimal revenue, ongoing losses, and negative free cash flow) and bearish technical signals (price below key moving averages and negative MACD). Reduced leverage (zero debt) and improved cash burn provide some offset, while valuation metrics are limited by the negative P/E and lack of dividend yield data.
Positive Factors
Improved leverage (zero debt)
Moving to zero debt materially improves financial flexibility over the medium term by removing interest obligations and covenant risk. For a clinical-stage biotech this reduces near-term liquidity strain and gives management more optionality to fund trials, partner, or time development milestones without debt servicing pressure.
Negative Factors
Effectively zero revenue
Absence of a revenue base leaves the company fully reliant on financing and partnerships to fund operations. That structural dependence raises dilution and execution risk over the medium term, since clinical success or commercialization milestones are required before organic cash generation can stabilize the business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage (zero debt)
Moving to zero debt materially improves financial flexibility over the medium term by removing interest obligations and covenant risk. For a clinical-stage biotech this reduces near-term liquidity strain and gives management more optionality to fund trials, partner, or time development milestones without debt servicing pressure.
Read all positive factors
Instil Bio (TIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$57.92M
Dividend YieldN/A
Average Volume (3M)28.64K
Price to Earnings (P/E)―
Beta (1Y)5.12
Revenue GrowthN/A
EPS Growth1.40%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.21
Shares Outstanding6,781,976
10 Day Avg. Volume32,493
30 Day Avg. Volume28,645
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap2.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.69K
Enterprise Value/Ebitda-2.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.53
Revenue Forecast (FY)N/A
Instil Bio Business Overview & Revenue Model
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline...
How the Company Makes Money
null...
Instil Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -534.00K | 0.00 | 0.00 | -5.99M | 0.00 |
| EBITDA | -52.37M | -62.53M | -147.12M | -217.38M | -152.51M |
| Net Income | -71.37M | -74.14M | -156.09M | -223.18M | -156.79M |
Balance Sheet | |||||
| Total Assets | 203.52M | 263.57M | 325.63M | 482.13M | 609.98M |
| Cash, Cash Equivalents and Short-Term Investments | 76.13M | 113.31M | 150.36M | 260.92M | 454.10M |
| Total Debt | 85.18M | 86.89M | 86.05M | 79.90M | 0.00 |
| Total Liabilities | 89.66M | 94.13M | 99.80M | 118.52M | 54.78M |
| Stockholders Equity | 113.87M | 169.44M | 225.83M | 363.61M | 555.20M |
Cash Flow | |||||
| Free Cash Flow | -36.62M | -65.70M | -102.69M | -264.75M | -179.97M |
| Operating Cash Flow | -36.62M | -55.70M | -82.03M | -180.16M | -122.14M |
| Investing Cash Flow | 25.48M | 53.97M | 41.13M | 114.54M | -474.40M |
| Financing Cash Flow | 7.29M | 1.75M | 8.08M | 71.89M | 393.16M |
Instil Bio Technical Analysis
Positive
8.03
Price Trends
8.27
Positive
9.36
Negative
16.29
Negative
Market Momentum
-0.05
Negative
52.82
Neutral
79.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Positive. The current price of 8.03 is below the 20-day moving average (MA) of 8.38, below the 50-day MA of 8.27, and below the 200-day MA of 16.29, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 52.82 is Neutral, neither overbought nor oversold. The STOCH value of 79.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TIL.
Instil Bio Risk Analysis
Instil Bio disclosed 70 risk factors in its most recent earnings report. Instil Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Instil Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $249.40M | -0.60 | -118.95% | ― | ― | 31.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $195.77M | -0.71 | -52.77% | ― | -33.76% | 17.54% | |
49 Neutral | $60.32M | -1.00 | -71.28% | ― | -10.03% | 11.06% | |
47 Neutral | $297.85M | -0.70 | ― | ― | -63.96% | -28.50% | |
44 Neutral | $164.68M | -1.32 | -30.02% | ― | ― | 25.84% | |
43 Neutral | $57.92M | -2.28 | -55.88% | ― | ― | 1.40% |
* Healthcare Sector Average
TIL
Instil Bio
8.54
-6.58
-43.52%
ZNTL
Zentalis Pharmaceuticals
2.76
1.59
135.90%
NKTX
Nkarta
2.31
0.74
47.13%
ALXO
ALX Oncology Holdings
1.90
1.38
264.42%
SRZN
Surrozen
25.93
16.48
174.39%
TCRX
TScan Therapeutics
1.06
-0.14
-11.67%
Instil Bio Corporate Events
Business Operations and Strategy
Instil Bio Ends Key Oncology Licensing Agreement with ImmuneOnco
Negative
Jan 6, 2026
On January 5, 2026, Instil Bio’s subsidiary Axion Bio and ImmuneOnco Biopharmaceuticals mutually terminated their August 1, 2024 license and collaboration agreement, which had granted Axion ex-China development and commercial rights to the d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.